There are 2867 resources available
265P - Phase II study of DHP107 oral paclitaxel compared to IV paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer (MBC): Opera (NCT03326102)
Presenter: Hope Rugo
Session: Poster session 02
266P - Real-world quality of life (QoL) in patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS
Presenter: Gabrielle Rocque
Session: Poster session 02
267P - AB-ITALY: The impact of drug-drug interaction on abemaciclib treatment in Italian real world experience
Presenter: Andrea Botticelli
Session: Poster session 02
269P - Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry
Presenter: Elena Laakmann
Session: Poster session 02
270P - Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort
Presenter: Linda Cucciniello
Session: Poster session 02
271P - Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study
Presenter: Ana Lopez Gonzalez
Session: Poster session 02
274TiP - Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01
Presenter: Aditya Bardia
Session: Poster session 02